Side-by-side comparison of AI visibility scores, market position, and capabilities
Newark NJ financial services (NYSE: PRU) ~$47.6B FY2024 revenue; PGIM $1.4T AUM, Japan/Brazil life insurance, Fortitude Re block sale, annuity demand surge competing with MetLife and Lincoln Financial.
Prudential Financial, Inc. is a Newark, New Jersey-based diversified financial services company — publicly traded on the New York Stock Exchange (NYSE: PRU) as an S&P 500 Financials component — providing life insurance, retirement solutions, investment management, and financial wellness services through PGIM (Prudential's global investment management arm, $1.4T AUM), Individual Retirement Strategies (annuities, guaranteed income products), Group Insurance (employer-sponsored life and disability insurance), and International Businesses (life insurance in Japan, Brazil, and emerging markets) through approximately 40,000 employees. In fiscal year 2024, Prudential Financial reported revenues of approximately $47.6 billion and adjusted operating income per share growth as the company executed its "higher growth, higher return, lower risk" strategic transformation: completing the sale of Prudential's US variable life insurance block to Fortitude Re, reducing the life insurance legacy reserve sensitivity that created earnings volatility during interest rate and equity market moves, while growing PGIM institutional asset management and individual retirement solutions. CEO Andy Sullivan (succeeded Charles Lowrey in April 2024) maintains the transformation strategy of concentrating Prudential on fee-based asset management (PGIM), annuity distribution, and international life insurance markets where Prudential holds leading positions — particularly Japan (life insurance through Prudential Life Insurance Company of Japan and Gibraltar Life) and Brazil (Icatu Seguros partnership). PGIM's $1.4 trillion in assets under management across fixed income, equity, real estate, and alternatives positions Prudential as one of the top 20 global asset managers — generating management fee revenue less correlated to interest rate movements than traditional life insurance spread income.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.